Avatrombopag
Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in 2018,[1][2] and in the European Union in 2019.[3]
![]() | |
Clinical data | |
---|---|
Pronunciation | a" va trom' boe pag |
Trade names | Doptelet |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618032 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C29H34Cl2N6O3S2 |
Molar mass | 649.65 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
References
- "FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2018. Retrieved 2 May 2020.
- "Drug Approval Package: Doptelet (avatrombopag)". U.S. Food and Drug Administration (FDA). 28 June 2018. Retrieved 2 May 2020.
- "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Retrieved 2 May 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.